Short-term Outcomes Of Intermittent Hemodialysis In Patients With Ventricular Assist Devices
HFSA ePoster Library. daSilva-deAbreu A. 09/10/21; 343646; 87
Adrian daSilva-deAbreu
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Background As more durable continuous flow (CF) left ventricular assist device (LVAD) are implanted, the number of implanting centers has increased. Whether center level characteristics influence post-implantation outcomes is not fully defined. Therefore, we sought to determine center level characteristics associated with risk standardized mortality rates (RSMR) at 1-month post-implant.
Methods Data from 167 centers that implanted CF-LVADs in 19,503 patients between 2008-2017 in the INTERMACS were analyzed. The 1-month post-implantation center RSMR was generated with a multivariable logistic regression model adjusting for 50 patient-level characteristics at implantation for all LVAD treatment strategies. Data from patients who were transplanted within 1-month or who had ≥5 missing variables were excluded. RSMR estimates underwent Bayesian correction to account for the influence of unbalanced inter-center CF LVAD volumes. Center-level characteristics were compared by the Cochran-Armitage trend or Chi-square tests across tertiles of the 1-month RSMR where appropriate.
Results The overall median [25-75th quartile] 1-month RSMR was 4% (1-6%). Median 1-month RSMR by center tertiles was 0% (0-1%), 4% (3-4%), and 7% (6-9%) respectively. Both greater annual and greater cumulative center LVAD volume were associated with lower 1-month RSMR (P <0.04 for both, figure A-B). Higher annual destination therapy CF-LVAD implantation volume (P=0.03), but not bridge-to-transplant CF-LVAD implantation volume (P=0.14) was associated with a lower 1-month RSMR. An implanting center’s percentage of destination therapy or bridge-to-transplant strategy CF-LVAD devices implanted was also not associated with 1-month RSMR (Figure C-F). Higher rates of a concomitant mitral valve repair, a sternal implant approach, and intraoperative ECMO or IABP removal were each associated with a lower 1-month RSMR (P<0.05 for all). Less cardiopulmonary bypass time (P<0.01), but not total surgical time (P=0.43) was associated with a lower 1-month RSMR. Lastly, there was no association with the percentage of patients with INTERMACs profile 1 and 1-month RSMR (P=0.80).
Conclusions When controlling for patient-level characteristics, higher LVAD implantation volumes, higher absolute rates of DT LVAD volumes, and certain patient-management strategies by center were associated with lower 1-month RSMR. These data identify potential patterns of care by center that may influence short-term post-LVAD outcomes.
Methods Data from 167 centers that implanted CF-LVADs in 19,503 patients between 2008-2017 in the INTERMACS were analyzed. The 1-month post-implantation center RSMR was generated with a multivariable logistic regression model adjusting for 50 patient-level characteristics at implantation for all LVAD treatment strategies. Data from patients who were transplanted within 1-month or who had ≥5 missing variables were excluded. RSMR estimates underwent Bayesian correction to account for the influence of unbalanced inter-center CF LVAD volumes. Center-level characteristics were compared by the Cochran-Armitage trend or Chi-square tests across tertiles of the 1-month RSMR where appropriate.
Results The overall median [25-75th quartile] 1-month RSMR was 4% (1-6%). Median 1-month RSMR by center tertiles was 0% (0-1%), 4% (3-4%), and 7% (6-9%) respectively. Both greater annual and greater cumulative center LVAD volume were associated with lower 1-month RSMR (P <0.04 for both, figure A-B). Higher annual destination therapy CF-LVAD implantation volume (P=0.03), but not bridge-to-transplant CF-LVAD implantation volume (P=0.14) was associated with a lower 1-month RSMR. An implanting center’s percentage of destination therapy or bridge-to-transplant strategy CF-LVAD devices implanted was also not associated with 1-month RSMR (Figure C-F). Higher rates of a concomitant mitral valve repair, a sternal implant approach, and intraoperative ECMO or IABP removal were each associated with a lower 1-month RSMR (P<0.05 for all). Less cardiopulmonary bypass time (P<0.01), but not total surgical time (P=0.43) was associated with a lower 1-month RSMR. Lastly, there was no association with the percentage of patients with INTERMACs profile 1 and 1-month RSMR (P=0.80).
Conclusions When controlling for patient-level characteristics, higher LVAD implantation volumes, higher absolute rates of DT LVAD volumes, and certain patient-management strategies by center were associated with lower 1-month RSMR. These data identify potential patterns of care by center that may influence short-term post-LVAD outcomes.
Background As more durable continuous flow (CF) left ventricular assist device (LVAD) are implanted, the number of implanting centers has increased. Whether center level characteristics influence post-implantation outcomes is not fully defined. Therefore, we sought to determine center level characteristics associated with risk standardized mortality rates (RSMR) at 1-month post-implant.
Methods Data from 167 centers that implanted CF-LVADs in 19,503 patients between 2008-2017 in the INTERMACS were analyzed. The 1-month post-implantation center RSMR was generated with a multivariable logistic regression model adjusting for 50 patient-level characteristics at implantation for all LVAD treatment strategies. Data from patients who were transplanted within 1-month or who had ≥5 missing variables were excluded. RSMR estimates underwent Bayesian correction to account for the influence of unbalanced inter-center CF LVAD volumes. Center-level characteristics were compared by the Cochran-Armitage trend or Chi-square tests across tertiles of the 1-month RSMR where appropriate.
Results The overall median [25-75th quartile] 1-month RSMR was 4% (1-6%). Median 1-month RSMR by center tertiles was 0% (0-1%), 4% (3-4%), and 7% (6-9%) respectively. Both greater annual and greater cumulative center LVAD volume were associated with lower 1-month RSMR (P <0.04 for both, figure A-B). Higher annual destination therapy CF-LVAD implantation volume (P=0.03), but not bridge-to-transplant CF-LVAD implantation volume (P=0.14) was associated with a lower 1-month RSMR. An implanting center’s percentage of destination therapy or bridge-to-transplant strategy CF-LVAD devices implanted was also not associated with 1-month RSMR (Figure C-F). Higher rates of a concomitant mitral valve repair, a sternal implant approach, and intraoperative ECMO or IABP removal were each associated with a lower 1-month RSMR (P<0.05 for all). Less cardiopulmonary bypass time (P<0.01), but not total surgical time (P=0.43) was associated with a lower 1-month RSMR. Lastly, there was no association with the percentage of patients with INTERMACs profile 1 and 1-month RSMR (P=0.80).
Conclusions When controlling for patient-level characteristics, higher LVAD implantation volumes, higher absolute rates of DT LVAD volumes, and certain patient-management strategies by center were associated with lower 1-month RSMR. These data identify potential patterns of care by center that may influence short-term post-LVAD outcomes.
Methods Data from 167 centers that implanted CF-LVADs in 19,503 patients between 2008-2017 in the INTERMACS were analyzed. The 1-month post-implantation center RSMR was generated with a multivariable logistic regression model adjusting for 50 patient-level characteristics at implantation for all LVAD treatment strategies. Data from patients who were transplanted within 1-month or who had ≥5 missing variables were excluded. RSMR estimates underwent Bayesian correction to account for the influence of unbalanced inter-center CF LVAD volumes. Center-level characteristics were compared by the Cochran-Armitage trend or Chi-square tests across tertiles of the 1-month RSMR where appropriate.
Results The overall median [25-75th quartile] 1-month RSMR was 4% (1-6%). Median 1-month RSMR by center tertiles was 0% (0-1%), 4% (3-4%), and 7% (6-9%) respectively. Both greater annual and greater cumulative center LVAD volume were associated with lower 1-month RSMR (P <0.04 for both, figure A-B). Higher annual destination therapy CF-LVAD implantation volume (P=0.03), but not bridge-to-transplant CF-LVAD implantation volume (P=0.14) was associated with a lower 1-month RSMR. An implanting center’s percentage of destination therapy or bridge-to-transplant strategy CF-LVAD devices implanted was also not associated with 1-month RSMR (Figure C-F). Higher rates of a concomitant mitral valve repair, a sternal implant approach, and intraoperative ECMO or IABP removal were each associated with a lower 1-month RSMR (P<0.05 for all). Less cardiopulmonary bypass time (P<0.01), but not total surgical time (P=0.43) was associated with a lower 1-month RSMR. Lastly, there was no association with the percentage of patients with INTERMACs profile 1 and 1-month RSMR (P=0.80).
Conclusions When controlling for patient-level characteristics, higher LVAD implantation volumes, higher absolute rates of DT LVAD volumes, and certain patient-management strategies by center were associated with lower 1-month RSMR. These data identify potential patterns of care by center that may influence short-term post-LVAD outcomes.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}